Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148593 | 0.90 | MGAM (0.36) | DHODHMGAMGAASIMGAM2 | |
| SCHEMBL1147862 | 0.85 | HSP90AA1 (0.38) | MGAMGAASIMGAM2KCNMA1 | |
| SCHEMBL1148407 | 0.83 | GAA (0.36) | MGAMGAASIMGAM2 | |
| SCHEMBL1148441 | 0.81 | MGAM (0.36) | MGAMGAASIMGAM2KCNMA1 | |
| SCHEMBL930756 | 0.81 | ESR1 (0.39) | DHODHKCNMA1 | |
| SCHEMBL1148449 | 0.81 | HSP90AA1 (0.33) | KCNMA1IDO1TDO2 | |
| SCHEMBL1148629 | 0.80 | ALOX5 (0.44) | DHODHKCNMA1 | |
| SCHEMBL1147778 | 0.80 | HSP90AA1 (0.37) | KCNMA1 | |
| SCHEMBL1147749 | 0.80 | HSP90AA1 (0.41) | DHODHKCNMA1 | |
| SCHEMBL1148426 | 0.80 | KCNN4 (0.36) | KCNMA1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | SYNTA PHARMACEUTICALS CORP (US) | 2015-04-02 | — | — | US | disclosed |
| US-8034834-B2 | Method for treating proliferative disorders with HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094349-A1 | Method for Treating Proliferative Disorders Associated with Protooncogene Products | HSP90AB1, HSP90AB2P, HSP90AA1 | DHODH 3214/4885MGAM 985/4885GAA 320/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | DHODH 3214/4885MGAM 985/4885GAA 320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.